Dennis Gillings, CBE, chairman and chief executive officer of Quintiles Transnational Corp., dedicated a new facility in Overland Park, KS, with Secretary David Kerr of the Kansas Department of Commerce.

The 236,000-sq.-ft. building will house Quintiles’ regional Clinical Development Services (CDS) and clinical pharmacology units previously located in Kansas City, MO, as well as the Phase I clinical research unit that had been in Lenexa, KS. The new Phase I unit has a 150-bed capacity—three times the size of the Lenexa unit—and can accommodate an additional 200 employees.

“The new facility gives the Overland Park office the room it needs to expand its activities in support of regional and global clinical research,” said Mr. Gillings. “Ultimately, however, this building is about even more than the creation of jobs in Overland Park and the growth of Quintiles, it’s about improving healthcare for people in Kansas, across the U.S. and around the world.”

Quintiles employs approximately 750 full-time workers in the Kansas City area in CDS, Clinical Pharmacology and Phase I.